Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfected with HIV?

Nature Clinical Practice Gastroenterology & Hepatology volume 1, pages 70–71 (2004)Cite this article

boxed-textTorriani FJ et al. (2004) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New Engl J Med 351: 438–450

Combination pegIFN and ribavirin therapy leads to an SVR and should be considered in suitable patients coinfected with HCV and HIV

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sulkowski MS and Thomas DL (2003) Hepatitis C in the HIV-infected person. Ann Intern Med 138: 197–207

    Article  Google Scholar 

  2. Landau A et al. (2001) Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 15: 2149–2155

    Article  CAS  Google Scholar 

  3. Manns MP et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965

    Article  CAS  Google Scholar 

  4. Fried MW et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982

    Article  CAS  Google Scholar 

  5. Chung RT et al. (2004) Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351: 451–459

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Minal Chande, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Director, GI/Hepatology Research at Duke University Medical Center, Durham, NC, USA

    John McHutchison

  2. Postdoctoral Hepatology Research Fellow, Duke Clinical Research Institute, Duke University, NC, USA

    Amany Zekry

Authors
  1. John McHutchison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amany Zekry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John McHutchison.

Glossary

HCV GENOTYPES

Genomic variation in HCV, determined by sequencing

NEUTROPENIA

An absolute neutrophil count below 2000 per cubic millimeter

THROMBOCYTOPENIA

Low platelet count (normal platelet count is between 150,000–450,000 platelets per cubic millimeter)

APRICOT TRIAL

AIDS Pegasys Ribavirin International Coinfection Trial

ACTG A5071

AIDS Clinical Trials Group A5071 Study Team

Rights and permissions

Reprints and permissions

About this article

Cite this article

McHutchison, J., Zekry, A. Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfected with HIV?. Nat Rev Gastroenterol Hepatol 1, 70–71 (2004). https://doi.org/10.1038/ncpgasthep0050

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0050

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing